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OBJECTIVE—Plasma kallikrein (PK) has been identiﬁed in vit-
reous ﬂuid obtained from individuals with diabetic retinopathy
and has been implicated in contributing to retinal vascular dys-
function. In this report, we examined the effects of PK on retinal
vascular functions and thickness in diabetic rats.
RESEARCH DESIGN AND METHODS—We investigated the
effects of a selective PK inhibitor, ASP-440, and C1 inhibitor
(C1-INH), the primary physiological inhibitor of PK, on retinal
vascular permeability (RVP) and hemodynamics in rats with
streptozotocin-induced diabetes. The effect of intravitreal PK in-
jection on retinal thickness was examined by spectral domain op-
tical coherence tomography.
RESULTS—Systemic continuous administration of ASP-440 for
4 weeks initiated at the time of diabetes onset inhibited RVP by
42% (P =0 . 0 1 3 )a n d8 3 %( P , 0.001) at doses of 0.25 and 0.6 mg/kg
per day, respectively. Administration of ASP-440 initiated 2 weeks
after the onset of diabetes ameliorated both RVP and retinal
blood ﬂow abnormalities in diabetic rats measured at 4 weeks’
diabetes duration. Intravitreal injection of C1-INH similarly de-
creased impaired RVP in rats with 2 weeks’ diabetes duration.
Intravitreal injection of PK increased both acute RVP and sus-
tained focal RVP (24 h postinjection) to a greater extent in diabetic
rats compared with nondiabetic control rats. Intravitreal injection
of PK increased retinal thickness compared with baseline to a
greater extent (P = 0.017) in diabetic rats (from 193 6 10 mmt o
223 6 13 mm) compared with nondiabetic rats (from 182 6 8 mm
to 193 6 9 mm).
CONCLUSIONS—These results show that PK contributes to
retinal vascular dysfunctions in diabetic rats and that the com-
bination of diabetes and intravitreal injection of PK in rats
induces retinal thickening. Diabetes 60:1590–1598, 2011
D
iabetic macular edema (DME) is a leading cause
of vision loss attributed to diabetes. The 14-year
incidence of this disease in individuals with
type 1 diabetes followed in the Wisconsin Epi-
demiologic Study of Diabetic Retinopathy was 26% (1), and
the progression to clinically signiﬁcant macular edema was
associated with increasing retinopathy severity (2). Al-
though intensive glycemic and blood pressure control can
reduce the incidence of DME (3) once this condition
develops, the treatment options include laser and vascular
endothelial growth factor (VEGF)-targeted therapies, which
provide substantial improvement in visual acuity for ~50%
of patients with DME (4). Thus, additional treatment options
for this disease are needed.
DME is associated with a loss of blood-retinal barrier
function, leading to increased diffusion of plasma compo-
nents, thickening of the macula, and impairment in central
vision (5,6). In addition to retinal thickening, increased
retinal vascular permeability (RVP) alters the biochemical
composition of the retinal interstitial ﬂuid and the vitreous.
Proteomic studies have begun to characterize the changes
in the vitreous protein composition in people with diabetic
retinopathy compared with nondiabetic subjects or diabe-
tic subjects without diabetic retinopathy (7). We have
previously reported an abundance of vasoactive plasma
proteins, including components of the plasma kallikrein
(PK)-kinin system (PKKS) in the vitreous of subjects with
advanced diabetic retinopathy (7,8). These ﬁndings have
suggested additional factors besides VEGF that may con-
tribute to the decline in blood-retinal barrier integrity and
vascular dysfunction in DME (9,10).
Plasma prekallikrein (PPK) is an abundant serine pro-
tease zymogen in blood that is converted to its catalytically
active form, PK, by factor XIIa (11), contributing to the
innate inﬂammatory response and intrinsic coagulation
cascades (12). The mechanisms that lead to the activation
of this pathway in vivo include interactions with poly-
phosphates released from activated platelets and deﬁ-
ciency of C1 inhibitor (C1-INH), the primary physiological
inhibitor of the PKKS (13,14). PK-mediated cleavage of
high-molecular weight kininogen generates the nonapeptide
bradykinin (BK), which activates the BK 2 (B2) receptor.
Subsequent cleavage of BK by carboxypeptidases generates
des-Arg
9-BK, which activates the B1 receptor. Both B1
and B2 receptors are expressed by vascular, glial, and
neuronal cell types, with the highest levels of retinal
expression detected in the ganglion cell layer and inner
and outer nuclear layers (15,16). Activation of B1 and B2
receptors causes vasodilation and increases vascular per-
meability (17–19). Previously, we have demonstrated that
intravitreal injection of carbonic anhydrase-1 (CA-1) in-
creased RVP and that this response was blocked by
the inhibition of PK and by BK receptor antagonists (8).
Recently, we reported that intravitreal injection of PK in-
creased RVP in nondiabetic rats, and systemic administra-
tion of a small-molecule PK inhibitor, ASP-440, decreased
RVP in rats subjected to angiotensin II (AngII)-induced hy-
pertension (19). In the current study, we investigated the
effects of PK on retinal vascular functions and retinal
thickness in diabetic rats.
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ORIGINAL ARTICLERESEARCH DESIGN AND METHODS
Diabetes induction. Male Sprague-Dawley rats (250–300 g) were obtained
from Taconic Farms (Hudson, NY). Diabetes was induced by intraperitoneal
injection of streptozotocin (STZ; Sigma-Aldrich, Milwaukee, WI) in 50 mmol/L
sodium citrate at 55 mg/kg after a 12-h overnight fast. Blood glucose was
measured by tail sampling using a One Touch Ultra glucometer 24 h after
injection of STZ. Rats with blood glucose values .250 mg/dL were considered
diabetic for the study. Anesthesia used for these experiments was an in-
tramuscular injection of ketamine (50 mg/kg; Bioniche Pharma, Lake Forest,
IL) and xylazine (10 mg/kg; Sigma-Aldrich). At the conclusion of the studies,
animals were killed by inhalation of carbon dioxide. The experimental pro-
tocols were approved by the Joslin Diabetes Center Institutional Animal Care
and Use Committee. All animals were handled and cared for in accordance
with the Association for Research in Vision and Ophthalmology Resolution on
the Use of Animals in Research.
AngII-induced hypertension model. Under anesthesia, each rat was im-
planted with a subcutaneous Alzet osmotic pump (model 1007D, 0.5 mL/h;
Durect Corporation, Cupertino, CA) containing either saline or AngII (18 mg/kg/h)
and a second Alzet osmotic pump containing either saline or the PK inhibitor
ASP-440 at 4 mg/mL (model 1007D, 0.5 mL/h or model 2001, 1 mL/h). Five days
after pump insertion, blood pressure was measured using a noninvasive blood
pressure-heart rate–monitoring system (UR-5000; Ueda Electronic, Tokyo,
Japan).
Primary and secondary intervention studies with the PK inhibitor ASP-
440. For the primary intervention study, diabetic and age-matched control rats
were randomly assigned on day 2 after STZ injection, and diabetic rats received
a subcutaneous Alzet osmotic pump (either model 2002 [0.5 mL/h] containing
ASP-440 at 5 mg/mL, model 2004 [0.25 mL/h] containing ASP-440 at 24 mg/mL,
or vehicle [10% polyethylene glycol/90% saline]). For the secondary inter-
vention study, a second set of rats with STZ-induced diabetes and age-matched
control rats was randomly assigned on day 14 after conﬁrmation of diabetes
and implanted with a subcutaneous Alzet osmotic pump (model 2002 [0.5 mL/h]
containing ASP-440 at 12 mg/mL or vehicle [10% polyethylene glycol/90%
saline]).
C1-INH intervention. After the onset of diabetes was conﬁrmed, nondiabetic
and diabetic rats that were under anesthesia received intravitreal injections of
human C1-INH (200 ng/eye; EMD Chemicals, Gibbstown, NJ) in one eye and
balanced salt solution (BSS) in the contralateral eye on days 2, 7, and 12. Under
sterile conditions, a 31-gauge needle was inserted into the vitreous pars plana,
and a 10-mL bolus of solution was slowly infused.
RVP measurements by Evans blue-dye permeation. The Evans blue-dye
permeation technique was used to quantify RVP (20). In brief, under anes-
thesia, each animal was infused with Evans blue dye (45 mg/kg) through an
indwelling jugular catheter. The dye was allowed to circulate for 2 h prior to
the time the rats were killed. After tissue ﬁxation, the eyes were enucleated.
Retinas were extracted with dimethyl formamide, and the resultant superna-
tant was used to determine Evans blue-dye content. Results are expressed as
the rate of plasma extravasation per unit weight of retinal tissue.
Retinal whole mounts. Rats with 3–4 weeks of diabetes and controls were
given 10-mL intravitreal injections of human PK (hPK) (50 ng/eye; Enzyme
Research, South Bend, IN) and BSS in the contralateral eye. After 24 h, 250 mL
of 2 3 10
6 Da ﬂuorescein isothiocyanate (FITC)-dextran (100 mg/mL FD2000S;
Sigma-Aldrich) were infused into the jugular vein and allowed to circulate for
2 min. Animals were rapidly killed and the eyes enucleated. Retinas were
dissected and mounted on slides with antifade mounting medium. Retinas
were scanned at 310 power, using a confocal ﬂuorescent microscope (Zeiss
Laser Scan Microscopy LSM 410).
Retinal blood ﬂow by video ﬂuorescein angiography. The video ﬂuores-
ceinangiographysystem,usingaRhodenstockscanninglaserophthalmoscope,
has been described previously (21). In brief, the left eye of an anesthetized rat
is dilated with 1% tropicamide, and a Hamilton syringe ﬁlled with 10% sodium
ﬂuorescein is attached to a jugular vein catheter. A 5-mL bolus of ﬂuorescein is
injected, and the resultant retinal angiogram is digitized and analyzed. Mean
circulation time (MCT) of the dye and primary artery and vein diameter is
measured at 1.5 disc diameters from the optic nerve head (ONH).
Acute RVP response to PK by vitreous ﬂuorophotometry. To measure
RVP, the eyes from rats with 4 weeks’ diabetes duration and age-matched
control rats were dilated and received intravitreal injections of 50 ng puriﬁed
hPK in one eye and BSS in the contralateral eye. Fifteen minutes after the
injection, 300 mL/kg 10% sodium ﬂuorescein was infused via a jugular vein
catheter. At 5, 15, and 25 min after dye infusion, RVP was measured by
quantifying vitreous ﬂuorescein levels by vitreous ﬂuorophotometry (VFP), as
described previously (8). We have previously shown that intravitreal injection
of human serum albumin and human C1-INH does not increase RVP (8).
To examine the efﬁcacy and selectivity of the PK inhibitor, ASP-440, toward
acute RVP induced by various permeability agents in nondiabetic rats, a 5-mL
intravitreal injection of 20 mmol/L ASP-440 or vehicle was administered at 10
min prior to a 5-mL intravitreal injection of hPK (50 ng), VEGF (0.04 ng/mL;
R&D Systems, Minneapolis, MN), or CA-1 (40 ng/mL; Sigma-Aldrich). At 10 min
after the injection of the permeability agents, ﬂuorescein dye was infused, and
VFP was measured after a 30-min circulation.
Effect of exogenous PK on retinal thickness. Baseline retinal scans were
made from anesthetized rats with 4 weeks’ diabetes duration and age-matched
controls using spectral domain–optical coherence tomography (SD-OCT)
(840SDOCT System; Bioptigen, Durham, NC). Rectangular volumes of each
retina were obtained consisting of 1000 A-scans by 100 B-scans over a 1.5 3
1.5 mm area centered upon the ONH. Retinal thickness was measured at
500 mm relative to the ONH at points deﬁned by calipers on the OCT-derived
en face image. At the intersection of the distance calipers and the corre-
sponding B-scan, retinal thickness was measured using calibrated calipers
from the retinal pigment epithelium (RPE) to the internal limiting membrane
(ILM). Four caliper measurements were taken at each site, corresponding to
the temporal, nasal, superior, and inferior quadrants of the retina. The meas-
urements were averaged to produce a single thickness value for each retina.
Retinal thickness false-color topographic maps were generated using semi-
automated image segmentation software based on a smoothing ﬁlter and
a Sobel operator method for edge detection in MATLAB from exported retinal
OCT images. Before segmentation, a median ﬁlter was applied to reduce
speckle noise and smooth the image data in the transverse direction. Edges
were detected using a modiﬁed Sobel operator by taking a weighted differ-
ence. Manual input and detected boundaries in neighboring A-scans were used
as constraints for the segmentation. Retinal thickness topographic maps were
generated by measuring the thickness from the ILM to the posterior edge of
the RPE.
PPK quantitation in plasma. Plasma was collected in citrate, and proteins
were separated by SDS-PAGE. Immunoblotting was performed using an anti-
body against KLKB1 (LS-C38312; Lifespan Biosciences, Seattle, WA). Results
were visualized by enhanced chemiluminescence (Cell Signaling, Danvers, MA).
Quantiﬁcation was performed using ImageQuant 5.1 (Molecular Dynamics,
Sunnyvale, CA).
Statistics. Statistical analysis was performed with SigmaStat statistical soft-
ware (Jandel, San Raphael, CA). Multiple group comparisons for statistical
signiﬁcance used Bonferroni correction for one-way ANOVA. Unpaired com-
parisons were made with the Student unpaired t test, and paired comparisons
were made with the Student paired t test. The Mann-Whitney rank sum test
was used for unequal variances. Differences were considered statistically
signiﬁcant when P , 0.05. Results are expressed as mean 6 SD.
RESULTS
Effect of PK inhibition by ASP-440 on AngII-induced
RVP. We examined the effective dose of ASP-440 on RVP
to Evans blue dye using an AngII-induced hypertension
(19). Infusion of AngII increased the systolic blood pres-
sure (SBP) of rats compared with vehicle controls (200 6
32 vs. 152 6 9 mmHg, P , 0.001). The SBP of rats coin-
fused with AngII and ASP-440 at 0.2 and 0.4 mg/kg per day
was 193 6 14 and 220 6 24 mmHg, respectively, which
was not signiﬁcantly different than the SBP in rats provided
with AngII alone (Supplementary Table 1). AngII infusion
for 7 days increased RVP by 97% compared with vehicle-
treated control rats (39.6 6 12.3 vs. 20.1 6 3.3 mL/g/h, P ,
0.001). Cotreatment with ASP-440 at 0.2 and 0.4 mg/kg per
day decreased the AngII-mediated increase in RVP in a dose-
dependent manner by 61% (27.6 6 9.1 mL/g/h, P = 0.015) and
90% (22.0 6 11.0 mL/g/h, P = 0.002) compared with AngII plus
vehicle-treated rats (Supplementary Fig. 1). RVP was similar
in vehicle- and ASP-440–treated normotensive control rats
(20.1 6 3.3 vs. 21.4 6 8.7 mL/g/h).
Effect of PK inhibition on RVP in diabetic rats. We
examined the effect of systemic administration of ASP-440
on RVP in rats with STZ-induced diabetes. Subcutaneous
osmotic pumps with ASP-440 were implanted 2 days after
STZ injection and delivered continuously for 4 weeks.
Blood glucose and body weights were similar compared
with rats receiving vehicle and ASP-440 (Supplementary
Fig. 2). Diabetes increased RVP to Evans blue by 2.6-fold
(P , 0.001) compared with age-matched control nondiabetic
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rats in a dose-dependent manner by 42% (P = 0.013) at 0.25
mg/kg per day and 83% (P , 0.001) at 0.6 mg/kg per day
compared with diabetic rats that received vehicle alone
(Fig. 1A). Next, we examined the effect of intervention
with subcutaneous osmotic pumps containing ASP-440
implanted after 2 weeks’ diabetes duration on RVP mea-
sured at 4 weeks’ diabetes duration. RVP in diabetic rats
that received ASP-440 (0.6 mg/kg per day) was decreased
by 56% (P = 0.011) compared with diabetic rats that re-
ceived vehicle (Fig. 1B).
Effects of PK inhibition on retinal hemodynamics.
Retinal hemodynamics were assessed by measurements of
MCT from retinal arteries to veins, measurements of pri-
mary retinal vessel diameters, and calculated RBF in rats
with 4 weeks’ diabetes duration in the absence or presence
of treatment from week 2 to 4 with ASP-440. We show that
MCT was prolonged (P , 0.001) and RBF was decreased
(P = 0.001) in diabetic rats compared with nondiabetic
control rats (Fig. 2), as described previously (22). Inter-
vention with ASP-440 resulted in partial normalization of
the diabetes-induced retinal hemodynamic changes, de-
creasing MCT (P = 0.015) and increasing RBF (P = 0.001)
compared with diabetic rats that received vehicle alone.
ASP-440 treatment in diabetic rats was also associated
with increased diameter of retinal arteries (9.7 6 0.7 vs.
8.7 6 0.7 pixels, P = 0.011) and veins (13.3 6 0.8 vs. 12.3 6
0.7 pixels, P = 0.03) compared with diabetic rats that re-
ceived vehicle alone.
Circulating PPK levels in diabetes. PPK levels in plasma
from both diabetic and nondiabetic rats were quantiﬁed.
We show that PPK protein levels measured by immunoblot
were increased by 74% (P = 0.005) in diabetic rats and 64%
(P = 0.027) in ASP-440–treated diabetic rats compared with
nondiabetic rats (Supplementary Fig. 3).
Effect of C1-INH on RVP in diabetic rats. C1-INH is the
primary physiological inhibitor of PK and plays a critical
role in suppressing plasma extravasation in areas of local
inﬂammation (14,23). We examined the effect of intra-
vitreal injection of C1-INH on RVP in both diabetic and
nondiabetic rats. RVP assessed by Evans blue-dye perme-
ation was increased after 2 weeks of diabetes compared
with nondiabetic controls (Fig. 3). We show that eyes that
received an intravitreal injection of C1-INH (200 ng) at
FIG. 1. A: Effect of the PK inhibitor ASP-440 on RVP in rats with
4 weeks’ diabetes duration and age-matched nondiabetic rats. Diabetes
was induced in rats by STZ injection. After conﬁrmation of diabetes,
rats received subcutaneous osmotic pumps (Alzet model 2004) con-
taining ASP-440 (0.25 or 0.6 mg/kg per day) or vehicle alone. Retinal
Evans blue-albumin permeation was measured on day 28 after treat-
ment. Diabetes treated with vehicle increased RVP by 2.6-fold (*P <
0.001) compared with nondiabetic controls. Dosing of diabetic rats with
ASP-440 at 0.25 and 0.6 mg/kg per day decreased RVP by 42% (tP =
0.011) and 83% (tP < 0.001), respectively, compared with vehicle-
treated diabetes. B: Effect of the PK inhibitor, ASP-440, by secondary
intervention on diabetes-induced RVP in diabetic rats with 4 weeks’
diabetes duration and age-matched nondiabetic rats. Two weeks after
the conﬁrmation of diabetes, rats received subcutaneous osmotic
pumps (Alzet model 2002) containing ASP-440 (0.6 mg/kg per day) or
vehicle alone. Retinal Evans blue-albumin permeation was measured on
day 28. Diabetic rats treated with vehicle had a 2.3-fold (*P = 0.002)
increase in RVP compared with the nondiabetic control rats. Treatment
of diabetic rats with ASP-440 decreased RVP by 56% (tP = 0.011)
compared with vehicle-treated diabetic rats. RVP measured in non-
diabetic control rats treated with ASP-440 at 0.6 mg/kg per day was not
signiﬁcantly different from that measured in vehicle-treated non-
diabetic control rats.
FIG. 2. Effect of ASP-440 by secondary intervention on diabetes-
mediated retinal hemodynamics. Diabetes was induced in rats by STZ
injection. Two weeks after the conﬁrmation of diabetes, rats received
subcutaneous osmotic pumps (Alzet model 2002) containing ASP-440
(0.6 mg/kg per day) or vehicle alone. After 4 weeks’ diabetes duration,
retinal hemodynamics was measured by VFA. MCT of ﬂuorescein dye
transit was measured from retinal angiograms. Primary vessel diame-
ters were measured by boundary-crossing algorithm. RBF was calcu-
lated from the average of segmental blood ﬂows. Diabetes (DM)
increased MCT by 1.5-fold (**P < 0.001) and decreased RBF by 40%
(**P = 0.001) compared with nondiabetic (NDM) controls. Treatment of
diabetes with ASP-440 improved MCT by 55% (*P = 0.015) and RBF by
86% (*P = 0.001), respectively, compared with vehicle (VEH)-treated
diabetes alone. a.u., arbitrary unit.
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0.003) decrease in RVP compared with contralateral eyes
that received control injections with saline vehicle. Intra-
vitreal injection of C1-INH did not signiﬁcantly affect RVP
in nondiabetic rats.
Effects of intravitreal injection of PK on RVP. We
examined the effects of intravitreal injection of PK, com-
pared with vehicle, on RVP in diabetic and nondiabetic
rats. We estimated the vitreous volume to be ~100 mL and
injected 50 ng hPK per eye. This concentration of PK in the
vitreous is comparable with 0.5 ng/mL PK levels that we
have detected in human diabetic retinopathy vitreous
(data not shown). We demonstrate that intravitreal in-
jection of hPK increased RVP in both nondiabetic and
diabetic rats, compared with eyes that received saline ve-
hicle injections (Fig. 4). It is noteworthy that we found that
the magnitude of RVP increase induced by intravitreal in-
jection of hPK in diabetic rats was signiﬁcantly greater than
that observed in nondiabetic rats (67 6 30 vs. 34 6 19%,
P = 0.037).
We next examined the effect of intravitreal injections
of ASP-440 or vehicle on RVP in nondiabetic rats induced
by subsequent intravitreal injections with hPK, CA-1, and
VEGF. Intravitreal injection with ASP-440 (20 mmol/L)
pretreatment decreased PK- and CA-1-induced RVP by 75
and 73% (P , 0.001), respectively, compared with PK and
CA-1 alone (Fig. 5). In contrast, ASP-440 did not alter
VEGF-induced RVP. These ﬁndings conﬁrm that PK in-
hibition blocks CA-1-mediated RVP (8) but not VEGF-
mediated RVP, which has been shown to be inhibited by
.95% after intravitreal injection of the protein kinase Cb
inhibitor, LY333531 (24). These results suggest that ASP-
440’s inhibition of either AngII-induced RVP or diabetes-
induced RVP proceeds via inhibition of endogenous PK
and not via a direct effect on endogenous VEGF or protein
kinase Cb.
The effects of PK on RVP were also assessed 24–48 h
postinjection by visualizing the leakage of FITC-dextran
(molecular mass 2 3 10
6 Da) conjugate. We show that eyes
subjected to intravitreal injection of PK displayed focal
areas of leakage to FITC-dextran that were not observed in
retinas from eyes that received saline vehicle injection
(Fig. 6). At least one area of focal leakage was observed on
retinal whole mounts in ﬁve of eight eyes injected with PK
compared with none of eight saline vehicle–injected eyes
in diabetic rats, indicating a sustained effect of intravitreal
PK on focal leakage. In nondiabetic rats, eyes injected with
PK had at least one area of focal leakage in two of eight
eyes compared with none of eight eyes injected with saline
vehicle. These ﬁndings show that intravitreal injection of
PK induced sustained focal leakage in both nondiabetic and
diabetic rats, with a trend for more leakage in diabetic rats.
Effect of intravitreal injection of PK on retinal
thickness. The effects of diabetes and intravitreal PK in-
jection on retinal thickness were examined using SD-OCT.
OCT scans were obtained for each retina at baseline and at
24 h postinjection. Retinal thickness measurements were
registered using en face images relative to the center of
the ONH (Figs. 7A–D). Representative en face images and
a corresponding B-scan at 500 mm superior to the ONH are
shown in Fig. 7 at 24 h postinjection for nondiabetic and
diabetic rats that received BSS (Fig. 7A and C)o rP K( F i g .
7B and D). B-scans illustrate a single caliper measure-
ment from RPE to ILM at the 500-mm intersection point.
FIG. 3. Effect of C1-INH interventional treatment on diabetes-induced
RVP. Diabetes was induced in rats by STZ injection. After conﬁrmation
of diabetes, rats were given 10-mL intravitreal injections of C1-INH
(200 ng/eye) and BSS in the contralateral eye on days 2, 7, and 12.
Retinal Evans blue-albumin permeation was measured on day 14 after
diabetes onset. Diabetes treated with BSS increased RVP by 2.4-fold
(**P < 0.001) compared with nondiabetic controls. Treatment of di-
abetes with C1-INH decreased RVP by 61% (tP = 0.003) compared with
BSS-treated diabetes. Treatment of nondiabetic controls with C1-INH
had no effect compared with nondiabetic BSS controls.
FIG. 4. Effect of exogenous PK on RVP in 4 weeks’ diabetes (DM) du-
ration and age-matched nondiabetic (NDM) rats. Diabetes was induced
in rats by STZ injection. After 4 weeks of diabetes, rats were given
10-mL intravitreal (IVT) injections of hPK (50 ng/eye) and BSS in the
contralateral eye. After 15 min, a bolus of 10% sodium ﬂuorescein was
infused into the jugular vein. Leakage of ﬂuorescein was measured in
the vitreal compartment by VFP at 5, 15, and 25 min after bolus in-
fusion. At 5 min after infusion, no difference was observed between PK
and BSS eyes for diabetes or nondiabetes. At 15 min postinfusion, PK-
induced leakage was 33 and 56% (**P < 0.001) greater than the BSS-
injected eye in nondiabetic and diabetic rats, respectively. At 25 min
postinfusion, diabetes with BSS leakage was greater than nondiabetes-
injected BSS (sP < 0.001). PK-induced leakage was 34% (*P < 0.01)
and 67% (**P < 0.001) greater than the BSS-injected eye in nondiabetic
and diabetic rats, respectively. The increase in PK-induced leakage
compared with BSS injection was greater in diabetic rats (tP = 0.037)
than in nondiabetic rats, indicating an increased retinal sensitivity to
the presence of PK. a.u., arbitrary unit.
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injection induced vascular dilation and tortuosity that
were not evident in the BSS control retina. Baseline ret-
inal thickness in nondiabetic and diabetic rats were 182 6 8
and 193 6 10 mm, respectively (P = 0.024) (Fig. 7E). The
reproducibility of measurements from consecutively ac-
quired SD-OCT images was 1.2 6 1.0 mm. Retinal thick-
ness in nondiabetic rats 24 h postintravitreal injection of
BSS or PK was 189 6 4 and 193 6 9 mm, respectively.
Retinal thicknesses in diabetic rats following BSS or PK
intravitreal injection was higher at 196 6 8 and 223 6 13 mm
(P , 0.01), respectively. Results are summarized in Sup-
plementary Table 2.
To further evaluate the regions of retinal thickness, an
edge-detection algorithm was applied to each B-scan to
identify the RPE and ILM boundaries. Point differences
between layers were measured along each B-scan, and the
results were compiled to create a retinal-thickness map.
Representative thickness maps for corresponding baseline
and 24-h post-PK injection are shown for nondiabetes (Fig.
8A and B) and diabetes (Fig. 8C and D), respectively.
Automated segmentation was not possible near the ONH
because of the absence of the RPE as a reference position
and the presence of hyaloid remnants. This region is in-
dicated in white. Thickness false-color topographic maps
illustrate diffuse PK-induced thickening throughout the
retina in both nondiabetic and diabetic rats. These thick-
ness topographic maps also show increased retinal thick-
ness coincident with primary vessels, which appeared
elevated above the plane of the nerve ﬁber layer and ap-
proximately uniform thickness between these vessels on
the 500-mm annulus in the inferior-superior and nasal-
temporal axes, corresponding to the locations of caliper
measurements indicated in Fig. 7.
DISCUSSION
This report provides the ﬁrst characterization of the effect
of PK inhibition on retinal vascular dysfunction in diabetes
and the effect of intravitreal injection of PK on retinal
thickness. We show that systemic administration of a se-
lective small-molecule PK inhibitor, ASP-440 (19), amelio-
rated both RVP and RBF abnormalities in diabetic rats.
Using a prevention protocol, continuous delivery of ASP-
440 for 4 weeks inhibited diabetes-induced increased RVP
by .80% without altering blood glucose or body weight.
Using an intervention protocol, we show that ASP-440
inhibited diabetes-induced RVP when treatment was initi-
ated 2 weeks after diabetes onset, although this did not
affect RVP compared with baseline in nondiabetic normal
rats. The efﬁcacious dose range of ASP-440 in diabetic rats
was comparable with that observed in rats with 7 days of
AngII-induced hypertension. Although ASP-440 inhibited
PK-induced RVP, it did not affect VEGF-induced RVP,
suggesting that its beneﬁcial effects on pathological RVP
are not a result of a direct inhibition of VEGF-induced
blood-retinal barrier permeability. These ﬁndings suggest
that PK activity contributes to the elevated levels of RVP
associated with both hyperglycemia and hypertension,
both of which are major risk factors for diabetic retinopa-
thy progression and DME (1,3), and also that systemic PK
inhibition does not alter RVP in normal, healthy animals.
We also show that intravitreal injection of C1-INH decreased
RVP in diabetic rats, suggesting that local intraocular acti-
vation of the PKKS contributes to increased RVP in diabetic
rats. We have previously shown that intravitreal injection
of C1-INH blocked CA-1–induced RVP (8), suggesting that
PK inhibition may also reduce RVP associated with retinal
hemorrhages, which often increase in number and severity
during diabetic retinopathy progression.
The effects of the PKKS on vascular permeability at sites
of vascular injury and inﬂammation have been attributed
FIG. 5. Effect of ASP-440 on PK-, CA-1-, and VEGF-induced RVP. Non-
diabetic rats were given 5-mL intravitreal injections of ASP-440 (20
mmol/L) and vehicle in the contralateral eye. After 10 min, a second
5-mL intravitreal injection of either CA-1 (200 ng/eye), PK (50 ng/eye),
or VEGF (0.2 ng/eye) was given in both eyes. After an additional 10 min,
a bolus of ﬂuorescein dye was infused into the jugular vein. At 30 min
after dye infusion, leakage of ﬂuorescein was measured in the vitreal
compartment by VFP. CA-1 and VEGF increased RVP by 3.1- and 4-fold,
respectively, compared with vehicle control (tP < 0.001). Pretreatment
with ASP-440 decreased CA-1–induced RVP by 75% (*P < 0.001) but
had no effect on VEGF-induced RVP. PK increased RVP by 126% com-
pared with vehicle control (sP < 0.05), and pretreatment with ASP-440
blocked this effect by 73% (**P < 0.001). a.u., arbitrary unit.
FIG. 6. Exogenous intravitreal PK (Kal) induces focal retinal leakage of
FITC-labeled dextran at 24 h after injection. After 4 weeks’ diabetes
duration, both diabetic (DM) and age-matched nondiabetic control rats
were given 10-mL intravitreal injections of PK (50 ng/eye) and BSS
in the contralateral eye. After 24 h, 250 mL23 10
6 Da FITC-dextran
(100 mg/mL) was infused into the jugular vein and allowed to circulate
for 2 min. Retinal whole mounts were prepared and imaged by confocal
microscopy. Nondiabetic control and diabetic eyes injected with BSS
display an intact vascular bed at 24 h postinjection. PK-injected eyes
display small focal areas of dextran extravasation in nondiabetic con-
trol and larger focal areas in diabetic retina. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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after intravitreal injection and resultant retinal thickness measurements. After 4 weeks’ diabetes duration, baseline SD-OCT scans of the retina
from each eye were obtained (100 B-scans of 1,000 A-scans over a 1.5 3 1.5 mm area). Rats were given 10-mL intravitreal injections of PK (50
ng/eye) and BSS in the contralateral eye. At 24 h after injection, repeat SD-OCT scans of the retina from each eye were obtained. A–D: The center
of the optic nerve was identiﬁed, and a 500-mm radius was drawn on the en face image as shown in. The intersection of the radii terminus and the
corresponding B-scan identiﬁed the retinal sites for thickness measurement. Retinal thickness was measured on the intersecting B-scan from the
RPE to the ILM using calipers calibrated in microns. En face images were saved for retinal registration between timed SD-OCT scans. En face and
B-scan slices are shown for nondiabetes (NDM) plus BSS (A), nondiabetes plus PK (B), diabetes (DM) plus BSS (C), and diabetes plus PK (D).
B-scans correspond to the horizontal green line shown on each en face image. A single caliper is drawn on the corresponding B-scan at the 500-mm
point from the ONH. B-scans of PK-treated nondiabetic and diabetic retina illustrate increased thickness compared with BSS alone. En face images
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B1 and B2 receptors are expressed in retina, and their
direct activation via intravitreal injections of BK and des-
Arg
9-BK, respectively, has been shown to increase RVP
(17,19). Abdouh et al. (17) have shown that retinal B1 re-
ceptor expression and des-Arg
9-BK–induced RVP were
increased in diabetic rats compared with nondiabetic
controls and that 7 days of systemic treatment with a B1
receptor antagonist signiﬁcantly reduced diabetes-induced
RVP. Likewise, Lawson et al. (25) reported that B1 re-
ceptor antagonism decreased RVP in Wistar rats with 4
weeks of STZ-induced diabetes. These reports suggest that
activation of the PKKS can increase RVP via both B1 and
B2 receptors and that diabetes appears to increase actions
mediated via the B1 receptor. However, although upregu-
lation of retinal B1 receptors has been demonstrated in
rodent models with short duration of diabetes (17,26),
there is no information currently available on retinal
B1 receptor expression levels in diabetic retinopathy in
humans. Kedzierska et al. (27) have reported that circu-
lating PPK levels are elevated in people with diabetic ret-
inopathy. In the current study, we show that PPK levels in
the plasma of diabetic rats were elevated compared with
nondiabetic control rats (Supplementary Fig. 3), which is
consistent with previous ﬁndings using STZ-induced di-
abetic Wistar rats (28,29). Lawson et al. (25,30) have
shown that systemic administration of the B1 antagonist
R-954 in diabetic rats decreased vascular permeability in
other organs, including aorta, heart, kidney, and skin.
Taken together, these ﬁndings suggest that systemic acti-
vation of the PKKS may contribute to increased vascular
permeability in multiple tissues that are associated with
diabetic vasculopathies.
We have previously shown that the retinal MCT, which
measures the rate of hemodynamics across the retinal
microvasculature, is prolonged, and the RBF is decreased
in diabetic rats with 2 weeks of STZ-induced diabetes (22).
In this report, we show that the abnormalities in MCT and
RBF were signiﬁcantly ameliorated in rats that received
ASP-440 for 2 weeks in the interventional protocol. It is
surprising that we found that ASP-440 increased retinal
vessel diameters in diabetic rats, suggesting that activation
of endogenous PK in diabetic rats leads to vasoconstric-
tion of retinal vessels. Although acute administration of BK
has been shown to increase retinal vessel diameters (26),
the effects of chronic PK activation and increased RVP on
retinal hemodynamics are not yet known. Although the role
of retinal hemodyamics on the pathology of diabetic reti-
nopathy is not fully understood, decreases in RBF have been
described for diabetic patients with no diabetic retinopathy
or mild nonproliferative diabetic retinopathy (31–33), sug-
gesting that it is associated with early retinal vascular
responses to diabetes and diabetic retinopathy. The re-
duction in RVP and the increase in RBF observed in diabetic
rats that received ASP-440 compared with vehicle-treated
diabetic controls show that PK inhibition ameliorates two
early retinal vascular abnormalities caused by diabetes.
We have reported previously (7,8) that PK, high-molecular
weight kininogen, and FXII are present at elevated levels
in vitreous ﬂuid obtained from people with diabetic reti-
nopathy. The vitreous in diabetic retinopathy contains a
number of proteins that have been shown to bind and
activate components of the PKKS, including collagen and
laminin (34,35), misfolded proteins (36), CA-1 (8), and heat
shock protein 90 (7,37). We have shown a high ratio of PK
relative to PPK in diabetic retinopathy vitreous (8), sug-
gesting that PPK within the vitreous is efﬁciently activated
to PK. Although the mechanisms contributing to PKKS
expression in the vitreous are not fully understood, in-
creased RVP in diabetes could enable diffusion of PKKS
components from the blood to the retinal interstitial ﬂuid
and into the vitreous. In this report, we demonstrate that
the magnitude of the acute increase in RVP to ﬂuorescein
and the prolonged increase in focal areas of RVP to FITC-
dextran conjugate 24 h post-PK intravitreal injection were
greater in diabetic rats compared with nondiabetic con-
trols. Recently, using a proteomics approach, we have
shown that PK induces the proteolysis of extracellular
matrix proteins released from astrocytes, including colla-
gen, ﬁbronectin, laminin, and nidogen (38). These ﬁndings
suggest that PK-induced proteolysis of basement mem-
brane may contribute to its sustained effects on the retina.
We demonstrate that intravitreal injection of PK in di-
abetic rats results in an increase in retinal thickness
measured using SD-OCT. We used two methods to evalu-
ate retinal thickness using SD-OCT data collected at
baseline and at 24 h after intravitreal injection. The ﬁrst
method involved the generation of a 500-mm annulus on
the fundus image centered on the ONH that was used to
deﬁne four regions for retinal thickness measurements
from B slices using calipers. By use of this approach, we
were able to perform image registration for pre- and post-
injection measurements of retinal thickness. This method
enabled reproducibility of retinal-thickness measurements
with a tolerance of 1–2 mm. In the second method, we used
an algorithm to automate segmentation of B slices and
compiled thickness data to generate thickness topographic
maps. Thicknesses were visualized using a colored-scale
heat map centered at 200 mm. This method provided the
advantage of a wider ﬁeld of visualization of retinal thick-
ness compared with the caliper approach described above.
These thickness maps indicated that PK-induced retinal
thickening was relatively uniform in all quadrants of the
retina. We show that PK intravitreal injection in diabetic
rats resulted in a marked increase in thickness compared
with both baseline measurements and to the response
observed in nondiabetic rats, a response consistent with
the PK-induced changes in RVP. Our results suggest that
the level of RVP induced by diabetes alone may not be
sufﬁcient to induce a robust increase in retinal thickness
in rats. This is consistent with clinical ﬁndings that
have demonstrated a correlation between DME and the
severity of RVP (39). Previous studies based on vitreous
proteomics have suggested that RVP and hemorrhage can
show vessel tortuosity and vascular dilation of the primary vasculature after PK injection compared with BSS-treated retina. E: Quantiﬁcation of
retinal thickness in diabetic and age-matched nondiabetic rats at baseline and 24 h after intravitreal injection of PK. Diabetes was induced in rats
by STZ injection. After 4 weeks of diabetes, baseline SD-OCT scans of the retina from each eye were obtained. Rats were given 10-mL intravitreal
injections of PK (50 ng/eye) and BSS in the contralateral eye. At 24 h postinjection, follow-up SD-OCT scans of the retina from each eye were
obtained. For BSS-treated eyes, retinal thickness increased at 24 h by 3.9% (*P < 0.05) and 2.5% (*P < 0.05) compared with baseline thickness in
nondiabetic and diabetic rats, respectively. For PK-treated eyes, retinal thickness increased at 24 h by 6.1% (**P < 0.01) and 15.8% (P < 0.01)
compared with baseline thickness in nondiabetic and diabetic rats, respectively. The increase in retinal thickness by PK in diabetes was greater
than the change observed in the contralateral BSS injection alone (tP = 0.002) and was greater than the effect of PK on thickness in nondiabetes
(sP = 0.017). (A high-quality digital representation of this ﬁgure is available in the online issue.)
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diabetes alone and that this additive effect may overwhelm
compensatory mechanisms that mediate retinal ﬂuid bal-
ance (8). Our results suggest that increased PK levels in
the vitreous may be one of the factors that contribute to
retinal thickening in diabetes.
In conclusion, this report shows that inhibition of PK
reduces RVP in diabetic rats and describes a new model of
FIG. 8. Representative false-color topographic thickness maps of rat retina obtained by SD-OCT illustrating the effect of exogenous PK on the
retina at 24 h after injection into the vitreous. Thickness maps were generated by using an edge-detection algorithm to identify the RPE and ILM
layers in each horizontal B-scan of a rectangular retinal volume. Thickness was calculated as a difference between points on the RPE and ILM along
an entire B-scan. Baseline and 24 h after PK injection thickness maps are shown for nondiabetic (A and B) and diabetic (C and D) rats, re-
spectively. Corresponding B-scans bisecting the ONH from each map are shown below. Exogenous PK increased retinal thickness uniformly across
the retina in both nondiabetes and diabetes and induced vascular dilation, as indicated by increased vessel thickness. B-scans illustrate an increase
in retinal thickness at the ONH rim at baseline and enhanced thickness at the ONH induced by PK at 24 h after injection. (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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jection of PK in diabetic rats. These ﬁndings suggest that
either systemic administration of a small-molecule PK in-
hibitor, such as ASP-440, or intravitreal injection of C1-INH,
a physiological PK inhibitor, may provide new pharmaceu-
tical treatment options to reduce RVP associated with di-
abetic retinopathy and DME.
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